{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:40:20Z","timestamp":1684474820604},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T00:00:00Z","timestamp":1308614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1038\/nrneurol.2011.93","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T11:59:45Z","timestamp":1308657585000},"page":"362-363","source":"Crossref","is-referenced-by-count":0,"title":["Clinical prognostic scales in Guillain\u2013Barr\u00e9 syndrome"],"prefix":"10.1038","volume":"7","author":[{"given":"Nortina","family":"Shahrizaila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,21]]},"reference":[{"key":"BFnrneurol201193_CR1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","volume":"6","author":"R van Koningsveld","year":"2007","unstructured":"van Koningsveld, R.  et al. A clinical prognostic scoring system for Guillain\u2013Barr\u00e9 syndrome. Lancet Neurol. 6, 589\u2013594 (2007).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol201193_CR2","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","volume":"76","author":"C Walgaard","year":"2011","unstructured":"Walgaard, C.  et al. Early recognition of poor prognosis in Guillain\u2013Barr\u00e9 syndrome. Neurology 76, 968\u2013975 (2011).","journal-title":"Neurology"},{"key":"BFnrneurol201193_CR3","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/brain\/awm004","volume":"130","author":"RA Hughes","year":"2007","unstructured":"Hughes, R. A.  et al. Immunotherapy for Guillain\u2013Barr\u00e9 syndrome: a systematic review. Brain 130, 2245\u20132257 (2007).","journal-title":"Brain"},{"key":"BFnrneurol201193_CR4","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1212\/WNL.51.6.1656","volume":"51","author":"S Kuwabara","year":"1998","unstructured":"Kuwabara, S.  et al. Two patterns of clinical recovery in Guillain\u2013Barr\u00e9 syndrome with IgG anti-GM1 antibody. Neurology 51, 1656\u20131660 (1998).","journal-title":"Neurology"},{"key":"BFnrneurol201193_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ana.410400209","volume":"40","author":"BC Jacobs","year":"1996","unstructured":"Jacobs, B. C.  et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain\u2013Barr\u00e9 syndrome. Ann. Neurol. 40, 181\u2013187 (1996).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201193_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jneuroim.2007.11.017","volume":"194","author":"BC Jacobs","year":"2008","unstructured":"Jacobs, B. C.  et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain\u2013Barr\u00e9 syndrome. J. Neuroimmunol. 194, 181\u2013190 (2008).","journal-title":"J. Neuroimmunol."},{"key":"BFnrneurol201193_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ana.21737","volume":"66","author":"K Kuitwaard","year":"2009","unstructured":"Kuitwaard, K.  et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain\u2013Barr\u00e9 syndrome. Ann. Neurol. 66, 597\u2013603 (2009).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201193_CR8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1212\/WNL.47.3.668","volume":"47","author":"LH Visser","year":"1996","unstructured":"Visser, L. H.  et al. Cytomegalovirus infection and Guillain\u2013Barr\u00e9 syndrome: the clinical, electrophysiologic, and prognostic features. Neurology 47, 668\u2013673 (1996).","journal-title":"Neurology"},{"key":"BFnrneurol201193_CR9","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1212\/WNL.56.6.758","volume":"56","author":"RD Hadden","year":"2001","unstructured":"Hadden, R. D.  et al. Preceding infections, immune factors, and outcome in Guillain\u2013Barr\u00e9 syndrome. Neurology 56, 758\u2013765 (2001).","journal-title":"Neurology"},{"key":"BFnrneurol201193_CR10","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1136\/jnnp.2010.213421","volume":"81","author":"S Kuwabara","year":"2010","unstructured":"Kuwabara, S. Axonal Guillain\u2013Barr\u00e9 syndrome is underestimated in Europe? J. Neurol. Neurosurg. Psychiatry 81, 1063 (2010).","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2011.93.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2011.93","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2011.93.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:03:55Z","timestamp":1684472635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2011.93"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,21]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["BFnrneurol201193"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2011.93","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,21]]}}}